Chemours Co is trading 5.1% down at $20.57 following a federal appeals court decision regarding chemical discharges at its Washington Works facility.
- The court ruling adds to the company's legal overhang, contributing to sustained selling pressure on the stock.
- Shares are also being weighed down by a sharp broader market pullback, with major U.S. indices falling between 1% and 3%.
- The decline reflects a combination of company-specific legal challenges and a general risk-off sentiment across the market.